Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Public ClinicalTrials.gov record NCT00434148. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease
Study identification
- NCT ID
- NCT00434148
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 162 participants
Conditions and interventions
Conditions
Interventions
- Pasireotide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2006
- Primary completion
- Feb 28, 2010
- Completion
- Apr 30, 2014
- Last update posted
- Mar 7, 2016
2006 – 2014
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University Medical Center Stanford Cancer Center (3) | Stanford | California | 94304 | — |
| University Chicago Hospital Dept. of Univ of Chicago | Chicago | Illinois | 60637 | — |
| Dana Farber Cancer Institute The Melanoma Program | Boston | Massachusetts | 02115 | — |
| Columbia University Medical Center- New York Presbyterian Columbia University DeptofMed | New York | New York | 10032 | — |
| Cleveland Clinic Foundation Dept. of Cleveland Clinic (6) | Cleveland | Ohio | 44195 | — |
| Oregon Health & Sciences University Dept.ofOregonHealth&SciencesU. | Portland | Oregon | 97239 | — |
| University of Texas Southwestern Medical Center Clinical-TranslationalRes.Ctr. | Dallas | Texas | 75390-8527 | — |
| University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(8) | Houston | Texas | 77030-4009 | — |
| Baylor College of Medicine | Houston | Texas | 77030 | — |
| Swedish Medical Center Dept.ofSeattle Neuroscience(2) | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00434148, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 7, 2016 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00434148 live on ClinicalTrials.gov.